Cargando…

Exploring potential applications of measles and rubella microarray patches (MR-MAPs): use case identification

INTRODUCTION: Innovative vaccine products will be critical in helping to address the existing implementation barriers that have prevented the achievement of the measles and rubella (MR) vaccine coverage targets. Overcoming those barriers will be necessary to achieve the “Immunization Agenda 2030” go...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malvolti, Stefano, Ko, Melissa, Menozzi-Arnaud, Marion, Mantel, Carsten, Jarrahian, Courtney, Amorij, Jean-Pierre, Giersing, Birgitte, Hasso-Agopsowicz, Mateusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291693/ https://www.ncbi.nlm.nih.gov/pubmed/37377552 http://dx.doi.org/10.3389/fpubh.2023.1165110

Ejemplares similares

Estimating the future global dose demand for measles–rubella microarray patches
por: Ko, Melissa, et al.
Publicado: (2023)

Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges
por: Hasso-Agopsowicz, Mateusz, et al.
Publicado: (2022)

Measles and rubella microarray array patches to increase vaccination coverage and achieve measles and rubella elimination in Africa
por: Richardson, Lauren Christine, et al.
Publicado: (2020)

Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries
por: Giersing, Birgitte, et al.
Publicado: (2021)

Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation
por: Fu, Han, et al.
Publicado: (2023)

Partial third nerve palsy after Measles Mumps Rubella vaccination
por: Manzotti, Francesca, et al.
Publicado: (2010)

Two-dose measles–rubella vaccine schedule for measles–rubella elimination
por: John, T. Jacob
Publicado: (2023)

A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination
por: Prausnitz, Mark R, et al.
Publicado: (2020)

An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles–Mumps–Rubella (MMR) Vaccination Instead of Current Measles–Rubella (MR) Vaccination
por: Oh, Chunghyeon, et al.
Publicado: (2022)

Serological Response to COVID-19 and Its Association With Measles-Rubella (MR)-Containing Vaccines
por: Shrivastava, Jahnavi, et al.
Publicado: (2023)

Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
por: Wang, Zhifang, et al.
Publicado: (2014)

LB8. Microarray Patch Delivery of Long-Acting HIV PrEP and Contraception
por: Rein-Weston, Annie, et al.
Publicado: (2019)

Purulent Bronchitis Complicating Measles and Rubella
Publicado: (1919)

Genetic Characterization of Measles and Rubella Viruses Detected Through Global Measles and Rubella Elimination Surveillance, 2016–2018
por: Brown, Kevin E., et al.
Publicado: (2019)

Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran
por: Saffar, Hana, et al.
Publicado: (2021)

Measles & rubella outbreaks in Maharashtra State, India
por: Vaidya, Sunil R., et al.
Publicado: (2016)

Rubella and Its Relations to Scarlet Fever and Measles
Publicado: (1908)

2017 Measles-Rubella Vaccination Campaign in India
por: Shrivastava, Saurabh RamBihariLal, et al.
Publicado: (2018)

Expansion of the measles and rubella laboratory network, India
por: Sharma, Deepa, et al.
Publicado: (2022)

Differential Diagnosis of Scarlet Fever, Measles and Rubella
Publicado: (1919)

Modified measles versus rubella versus atypical measles: One and same thing
por: Gupta, Surender Nikhil, et al.
Publicado: (2015)

Case fatality risk of diarrhoeal pathogens: a systematic review and meta-analysis
por: Asare, Ernest O, et al.
Publicado: (2022)

The impact of Measles-Rubella vaccination on the morbidity and mortality from Congenital Rubella Syndrome in 92 countries
por: Vynnycky, Emilia, et al.
Publicado: (2018)

Mass Measles Rubella Immunization Campaign: Bhutan Experience
por: Giri, Bhakta R, et al.
Publicado: (2011)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Characterizing the dynamics of rubella relative to measles: the role of stochasticity
por: Rozhnova, Ganna, et al.
Publicado: (2013)

Strengthening routine immunization through measles-rubella elimination
por: Biellik, Robin J., et al.
Publicado: (2018)

Measles-Rubella vaccination campaign: A trust deficit?
por: Sreedevi, A
Publicado: (2018)

Is it time to reconsider measles, mumps, and rubella immunisation strategies?
por: Boccalini, Sara, et al.
Publicado: (2021)

Measles-Mumps-Rubella Vaccine and COVID-19 Relationship
por: Özdemir, Öner
Publicado: (2020)

Towards elimination of measles and rubella in Italy: Progress and challenges
por: Adamo, Giovanna, et al.
Publicado: (2019)

Cost of conducting Measles-Rubella vaccination campaign in India
por: Chatterjee, Susmita, et al.
Publicado: (2021)

Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study
por: Verma, Santosh Kumar, et al.
Publicado: (2023)

1148. Long-term Persistence of Measles and Rubella Virus Neutralizing Antibody Levels among Adults with Three Doses of Measles-Mumps-Rubella Vaccine
por: Alonge, Oluwakemi, et al.
Publicado: (2023)

Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]
por: Adigweme, Ikechukwu, et al.
Publicado: (2022)

Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial
por: Baker, Ben, et al.
Publicado: (2023)

Microarray patch for HIV prevention and as a multipurpose prevention technology to prevent HIV and unplanned pregnancy: an assessment of potential acceptability, usability, and programmatic fit in Kenya
por: Gachigua, Sammy Gakero, et al.
Publicado: (2023)

2467. Timeliness of Childhood Vaccination With the Combination Measles–Mumps–Rubella–Varicella Vaccine vs. the Separate Measles–Mumps–Rubella and Varicella Vaccines in the United States
por: Wolfson, Lara, et al.
Publicado: (2018)

Early Onset Optic Neuritis Following Measles-Rubella Vaccination
por: Moradian, Siamak, et al.
Publicado: (2008)

Resurgence risk for measles, mumps and rubella in France in 2018 and 2020
por: Béraud, Guillaume, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3lt4djnhpalrq206anems6c6b7